EXEL vs. TEVA: Exelixis vs. Teva Pharmaceutical Stock Comparison

Company Profile

Exelixis (EXEL) and Teva Pharmaceutical (TEVA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but EXEL is classified in Biotechnology while TEVA is classified in Pharmaceuticals.

Exelixis (EXEL) trades as ordinary local shares, while Teva Pharmaceutical (TEVA) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Exelixis (EXEL) at 44.32% and Teva Pharmaceutical (TEVA) at 6.65% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Exelixis (EXEL) at 35.45% converts revenue to bottom-line profit above its industry’s benchmark range, while Teva Pharmaceutical (TEVA) at 2.94% keeps roughly the typical share for its industry.

Both Exelixis (EXEL) at 40.75% and Teva Pharmaceutical (TEVA) at 27.40% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Exelixis (EXEL) at 6.98% and Teva Pharmaceutical (TEVA) at 4.31% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Exelixis (EXEL) reports EPS growth of 57.95%, ranked against its industry; Teva Pharmaceutical (TEVA) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Exelixis (EXEL) at 3.21 keeps current ratio within its industry’s typical mid-range, while Teva Pharmaceutical (TEVA) at 0.95 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TEVA.

Exelixis (EXEL) at 0.09 is near its industry mid-range for debt-to-equity ratio, while Teva Pharmaceutical (TEVA) at 2.13 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Neither Exelixis (EXEL) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Exelixis (EXEL) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Exelixis (EXEL) at 20.83 is near its industry’s usual P/E ratio, while Teva Pharmaceutical (TEVA) at 99.09 sits above its peer range — an unusually expensive price for TEVA’s trailing earnings.

Teva Pharmaceutical (TEVA) at 2.89 sits in the cheaper P/S ratio quartile while Exelixis (EXEL) at 6.80 prices around its industry’s middle — TEVA costs less per dollar of sales, though read it alongside growth and margins.

Teva Pharmaceutical (TEVA) at 6.23 is valued about in line with its industry on P/B ratio, while Exelixis (EXEL) at 9.28 carries an above-peer premium to book — EXEL is pricier on assets.

Valuation Metrics